NCT04594928View on ClinicalTrials.gov

A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 19, 2020

Primary Completion Date

May 4, 2021

Study Completion Date

May 4, 2021

Conditions
Plaque Psoriasis
Interventions
DRUG

GLPG3667

GLPG3667 capsules

DRUG

Placebo

Matching placebo capsules

Trial Locations (7)

1612

MC Comac Medical Ltd., Sofia

80-214

Early Clinical Trials Unit University Clinical Centre, Gdansk

31-559

Barbara Rewerska Diamond Clinic Specjalistyczne Poradnie Lekarskie, Krakow

94-048

Centrum Medyczne All-Med, Lodz

20-607

Reumed Sp. z o. o., Lublin

00-728

WIP Warsaw IBD Point, Warsaw

831 01

Summit Clinical Research, s.r.o., Bratislava

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY

NCT04594928 - A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter